These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 37567599)

  • 1. Patterns of spread and genetic alterations of primary endometrioid carcinomas of the ovary.
    Mazina V; Devins K; Philp L; Bercow AS; James K; Bregar A; Sisodia RC; Oliva E; Del Carmen M
    Int J Gynecol Cancer; 2023 Sep; 33(9):1434-1439. PubMed ID: 37567599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymph node staging in grade 1-2 endometrioid ovarian carcinoma apparently confined to the ovary: Is it worth?
    Bizzarri N; Imterat M; Fruscio R; Giannarelli D; Perrone AM; Mancari R; Traut A; Rosati A; du Bois A; Ferrari D; De Iaco P; Ergasti R; Ataseven B; Bianchi T; Di Stanislao M; Perri MT; Heitz F; Concin N; Fanfani F; Vizza E; Scambia G; Harter P; Fagotti A
    Eur J Cancer; 2023 Dec; 195():113398. PubMed ID: 37890354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Synchronous primary cancers of the endometrium and ovary: review of 43 cases].
    Ma SK; Zhang HT; Sun YC; Wu LY
    Zhonghua Zhong Liu Za Zhi; 2008 Sep; 30(9):690-4. PubMed ID: 19173912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is lymphadenectomy a prognostic marker in endometrioid adenocarcinoma of the human endometrium?
    Bassarak N; Blankenstein T; Brüning A; Dian D; Bergauer F; Friese K; Mylonas I
    BMC Cancer; 2010 May; 10():224. PubMed ID: 20492712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progression Free Survival, Overall Survival, and Relapse Rate in Endometrioid Ovarian Cancer and Synchronous Endometrial-Ovarian Endometrioid Cancer (SEO-EC): Results from a Large Retrospective Analysis.
    Pecorino B; Laganà AS; Chiantera V; Ferrara M; Di Stefano AB; Di Donna MC; Sorrentino F; Nappi L; Mikuš M; Scollo P
    Medicina (Kaunas); 2022 Nov; 58(12):. PubMed ID: 36556908
    [No Abstract]   [Full Text] [Related]  

  • 6. Does complete-staging lymphadenectomy improve survival outcomes in stage I endometrioid epithelial ovarian carcinoma? A multi-institutional retrospective study with propensity score-weighted analysis.
    Yoshihara M; Tamauchi S; Iyoshi S; Kitami K; Uno K; Tano S; Matsui S; Kajiyama H
    Jpn J Clin Oncol; 2021 Mar; 51(3):387-392. PubMed ID: 33253382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes and relapse patterns of stage IB grade 2 or 3 endometrial cancer treated with adjuvant vaginal brachytherapy.
    Hochreiter A; Kelly JR; Young MR; Litkouhi B; Black JD; Stromberger C; Higgins S; Schwartz PE; Damast S
    Int J Gynecol Cancer; 2020 Jan; 30(1):48-55. PubMed ID: 31722964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of pelvic lymph node metastasis using modern FIGO staging and sentinel lymph node mapping with ultrastaging in surgically staged patients with endometrioid and serous endometrial carcinoma.
    Mueller JJ; Pedra Nobre S; Braxton K; Alektiar KM; Leitao MM; Aghajanian C; Ellenson LH; Abu-Rustum NR
    Gynecol Oncol; 2020 Jun; 157(3):619-623. PubMed ID: 32247604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for lymph node metastasis in apparent early-stage epithelial ovarian cancer: implications for surgical staging.
    Powless CA; Aletti GD; Bakkum-Gamez JN; Cliby WA
    Gynecol Oncol; 2011 Sep; 122(3):536-40. PubMed ID: 21636114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival impact based on the thoroughness of pelvic lymphadenectomy in intermediate- or high-risk groups of endometrioid-type endometrial cancer: A multi-center retrospective cohort analysis.
    Kim TH; Kim HS; Kim TJ; Chang SJ; Kim DY; Ryu SY; Kim BG; Kim YT; Bae DS; Ryu HS; Nam JH
    Gynecol Oncol; 2016 Jun; 141(3):440-446. PubMed ID: 27020700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should all endometrioid uterine cancer patients undergo systemic lymphadenectomy?
    Wang ZQ; Wang JL; Shen DH; Li XP; Wei LH
    Eur J Surg Oncol; 2013 Apr; 39(4):344-9. PubMed ID: 23333067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sentinel-node biopsy in early-stage ovarian cancer: preliminary results of a prospective multicentre study (SELLY).
    Uccella S; Nero C; Vizza E; Vargiu V; Corrado G; Bizzarri N; Ghezzi F; Cosentino F; Turco LC; Fagotti A; Scambia G
    Am J Obstet Gynecol; 2019 Oct; 221(4):324.e1-324.e10. PubMed ID: 31082385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic impact of pelvic and para-aortic lymphadenectomy on clinically-apparent stage I primary mucinous epithelial ovarian carcinoma: a multi-institutional study with propensity score-weighted analysis.
    Yoshihara M; Kajiyama H; Tamauchi S; Iyoshi S; Yokoi A; Suzuki S; Kawai M; Nagasaka T; Takahashi K; Matsui S; Kikkawa F
    Jpn J Clin Oncol; 2020 Feb; 50(2):145-151. PubMed ID: 31688935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is there a difference in outcome between stage I-II endometrial cancer of papillary serous/clear cell and endometrioid FIGO Grade 3 cancer?
    Alektiar KM; McKee A; Lin O; Venkatraman E; Zelefsky MJ; McKee B; Hoskins WJ; Barakat RR
    Int J Radiat Oncol Biol Phys; 2002 Sep; 54(1):79-85. PubMed ID: 12182977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymphadenectomy in Early-Stage Intermediate-/High-Risk Endometrioid Endometrial Cancer: Clinical Characteristics and Outcomes in an Australian Cohort.
    Farrell R; Dixon SC; Carter J; Webb PM
    Int J Gynecol Cancer; 2017 Sep; 27(7):1379-1386. PubMed ID: 30814240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymph Node Involvement Pattern and Survival Differences of FIGO IIIC and FIGO IIIA1 Ovarian Cancer Patients After Primary Complete Tumor Debulking Surgery: A 10-Year Retrospective Analysis of the Tumor Bank Ovarian Cancer Network.
    Gasimli K; Braicu EI; Nassir M; Richter R; Babayeva A; Chekerov R; Darb-Esfahani S; Sehouli J; Muallem MZ
    Ann Surg Oncol; 2016 Apr; 23(4):1279-86. PubMed ID: 26832880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The incidence of pelvic and para-aortic lymph node metastasis in uterine papillary serous and clear cell carcinoma according to the SEER registry.
    Mattes MD; Lee JC; Metzger DJ; Ashamalla H; Katsoulakis E
    J Gynecol Oncol; 2015 Jan; 26(1):19-24. PubMed ID: 25310855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of complete surgical staging and adjuvant chemotherapy on survival in stage I, grade 1 and 2 endometrioid ovarian carcinoma.
    Swift BE; Covens A; Mintsopoulos V; Parra-Herran C; Bernardini MQ; Nofech-Mozes S; Hogen L
    Int J Gynecol Cancer; 2022 Apr; 32(4):525-531. PubMed ID: 34969829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term survival in patients with para-aortic lymph node metastasis with systematic retroperitoneal lymphadenectomy followed by adjuvant chemotherapy in endometrial carcinoma.
    Hiura M; Nogawa T; Matsumoto T; Yokoyama T; Shiroyama Y; Wroblewski J
    Int J Gynecol Cancer; 2010 Aug; 20(6):1000-5. PubMed ID: 20683408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of lymphadenectomy in uterine endometrioid carcinoma.
    Huang CY; Ho CM; Chen YL; You SL; Chen CA; Cheng WF
    Eur J Surg Oncol; 2013 Apr; 39(4):350-7. PubMed ID: 23462243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.